4//SEC Filing
SALIX PHARMACEUTICALS LTD 4
Accession 0001209191-14-003013
CIK 0001009356operating
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 9:42 PM ET
Size
13.0 KB
Accession
0001209191-14-003013
Insider Transaction Report
Form 4
DERBYSHIRE ADAM C
EVP Finance/CFO
Transactions
- Exercise/Conversion
Option to Buy Common Stock
2014-01-09−30,001→ 0 totalExercise: $18.87Exp: 2014-06-17→ Common Stock (30,001 underlying) - Sale
Common Stock
2014-01-09$91.95/sh−2,400$220,680→ 206,996 total - Exercise/Conversion
Common Stock
2014-01-09$18.87/sh+30,001$566,218→ 209,396 total - Sale
Common Stock
2014-01-09$91.44/sh−27,601$2,523,835→ 179,395 total
Holdings
- 20,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (20,000 underlying)
Footnotes (5)
- [F1]The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2013.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.91 to $92.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.91 to $91.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]Options are 100% vested.
- [F5]The reporting person's prior Forms 4 mistakenly indicated the total number of derivative securities beneficially owned was 30,000 when in fact the total number of derivative securities beneficially owned is 30,001. The reporting person's transactions and derivative security holdings reported herein reflect the correct information as of the date hereof.
Documents
Issuer
SALIX PHARMACEUTICALS LTD
CIK 0001009356
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001009356
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 9:42 PM ET
- Size
- 13.0 KB